Entera Bio Ltd. has 6 Schedule 13D or 13G filings on record since 2025-11-14. 3 holders' latest filing reports 5% or more of ordinary shares, par value of nis 0.0000769. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Biotechnology Value Fund L P | 9.99% | 9,171,741 | SCHEDULE 13D, 2026-08-04 | 2026-07-28 |
| TCG Crossover GP III, LLC | 7.1% | 12,254,901 | SCHEDULE 13G, 2026-08-04 | 2026-07-28 |
| Vivo Opportunity, LLC | 6.9% | 11,817,401 | SCHEDULE 13G, 2026-08-04 | 2026-07-28 |
| Longitude Capital Partners V, LLC | 4.6% | 7,843,138 | SCHEDULE 13G, 2026-08-04 | 2026-07-28 |
| Seven Fleet Capital Management LP | 4.1% | 7,053,898 | SCHEDULE 13G, 2026-08-04 | 2026-07-28 |
| Point72 Asset Management, L.P. | 2.6% | 1,183,116 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
Purpose of Transaction (Item 4)
Biotechnology Value Fund L P
The Reporting Persons purchased the securities reported owned herein based on the Reporting Persons' belief that such securities, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable. April Securities Purchase Agreement and Registration Rights Agreement On April 1, 2026, the Issuer entered into a Securities Purchase Agreement (the "April Securities Purchase Agreement") with certain of the Reporting Persons providing for the private placement (the "April Private Placement") to the applicable Reporting Persons of an aggregate of 7,827,789 units (collectively, the "Units"), each Unit consisting of (i) one Share (or, in lieu thereof, one pre-funded warrant to purchase one Share (the "April Pre-Funded Warrants")) and (ii) one warrant to purchase one and a half Shares (the "Warrants"), for aggregate proceeds of approximately $10.0 million (or $1.2775 per Unit). The closing of the April Private Placement occurred on April 2, 2026 (the "April Closing Date"). On …The first part of Item 4 of the SCHEDULE 13D filed 2026-08-04; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-11-14 | Point72 Asset Management, L.P. | 2.6% | SCHEDULE 13G/A |
| 2026-08-04 | Biotechnology Value Fund L P | 9.99% | SCHEDULE 13D |
| 2026-08-04 | Seven Fleet Capital Management LP | 4.1% | SCHEDULE 13G |
| 2026-08-04 | TCG Crossover GP III, LLC | 7.1% | SCHEDULE 13G |
| 2026-08-04 | Longitude Capital Partners V, LLC | 4.6% | SCHEDULE 13G |
| 2026-08-04 | Vivo Opportunity, LLC | 6.9% | SCHEDULE 13G |
Tools for this story
Each opens in a new tab, filled in for Entera Bio Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.